Evidence map›Paper›PMID 32541132›Full record

Trial reportMedical gas research

Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer.

Ji-Bing Chen, Xiao-Feng Kong, Feng Mu, Tian-Yu Lu, You-Yong Lu, Ke-Cheng Xu

Open access · hybridAbstract readClinical Trial
In one paragraph

Trial report in Medical gas research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. A Systematic Review of Molecular Hydrogen Therapy in Cancer Management.Asian Pacific journal of cancer prevention : APJCP · 2023
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Molecular Hydrogen in the Treatment of Respiratory Diseases.International journal of molecular sciences · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Observational
  19. Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases.Oxidative medicine and cellular longevity · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ji-Bing ChenFuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.
Xiao-Feng KongFuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
Feng MuFuda Cancer Hospital of Jinan University, Guangzhou, Guangdong Province, China.
Tian-Yu LuFuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.
You-Yong LuCentral Lab, Beijing Cancer Hospital, Beijing, China.
Ke-Cheng XuFuda Cancer Hospital of Jinan University, Guangzhou; Fuda Cancer Institute, Guangzhou, Guangdong Province, China.
Fuda Cancer Hospital · CNPeking University Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemotherapy, targeted therapy, and immunotherapy are used against advanced non-small cell lung cancer. A clinically efficacious method for relieving the adverse events associated of such therapies is lacking. Fifty-eight adult patients were enrolled in our trial to relieve pulmonary symptoms or the adverse events of drugs. Twenty patients who refused drug treatment were assigned equally and randomly to a hydrogen (H

Indexed as

Disease ProgressionAdministration, InhalationAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Non-Small-Cell LungFemaleHumansHydrogenLung NeoplasmsMaleMiddle AgedAntineoplastic AgentsHydrogenadverse eventchemotherapyhydrogenimmunotherapynon-small-cell lung cancerNSCLCPFSprogression-free survivaltargeted drug

Identifiers

PMID32541132
PMCPMC7885710
OpenAlexW3033825698

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.